Incremental cost-effectiveness ratios (ICERs): The silence of the lambda

Social Science and Medicine

Volumn 62, Issue 9, 2006, Pages 2091-2100

  Gafni, Amiram ^a   Birch, Stephen ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Cost effectiveness analysis; Decision rules; Economic evaluation; Health care costs; Incremental cost effectiveness ratio

Indexed keywords

HEALTH CARE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DECISION MAKING; HEALTH CARE SYSTEM; HEALTH PROGRAM; INFORMATION SCIENCE; SKULL SUTURE;

COST-BENEFIT ANALYSIS; DATA INTERPRETATION, STATISTICAL; DECISION MAKING, ORGANIZATIONAL; HEALTH CARE COSTS; HEALTH CARE RATIONING; MODELS, STATISTICAL; ONTARIO; QUALITY-ADJUSTED LIFE YEARS;

EID: 33644893894     PISSN: 02779536     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.socscimed.2005.10.023     Document Type: Article

References (53)

1. S. Birch, and C. Donaldson Valuing the benefits and costs of health care programmes: Where's the 'extra' in extra-welfarism? Social Science & Medicine 56 2003 1121 1133
2. S. Birch, and A. Gafni Cost effectiveness/utility analysis: Do current decision rules lead us to where we want to be? Journal of Health Economics 11 1992 279 296
3. S. Birch, and A. Gafni Changing the problem to fit the solution: Johannesson and Weinstein's (mis)application of economics to real world problems Journal of Health Economics 12 1993 469 476
4. S. Birch, and A. Gafni On being NICE in the UK: Guidelines for technology appraisal for the NHS in England and Wales Health Economics 11 2002 185 191
5. S. Birch, and A. Gafni Economics and the evaluation of health care programmes: Generalizability of methods and implications for generalizability of results Health Policy 64 2003 207 219
6. S. Birch, J. Melnikow, and M. Kupperman Conservative versus aggressive follow-up of mildly abnormal Pap smears: Testing for process utility Health Economics 12 2003 879 884
7. H. Bleichrodt, and J. Quiggin Life-cycle preferences over consumption and health: When is cost effectiveness analysis equivalent to cost benefit analysis? Journal of Health Economics 18 1999 681 708
8. A. Briggs A Bayesian approach to stochastic cost-effectiveness analysis Health Economics 8 1999 257 261
9. A.H. Briggs, and A.M. Gray Power and sample size calculations for stochastic cost-effectiveness analysis Medical Decision Making 18 1998 S81 S92
10. A.H. Briggs, R. Goeree, G. Blackhouse, and B.J. O'Brien Probabilistic analysis of cost effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease Medical Decision Making 22 2002 290 308
11. R. Cookson, D. McDaid, and A. Maynard Worng SIGN, NICE mess: Is national guidance distorting allocation of resources? British Medical Journal 323 2001 743 745
12. T. Culyer Introduction: Ought NICE to have a cost-effectiveness threshold? A. Towse C. Pritchard N. Devlin Cost effectiveness thresholds: Economics and ethical issues 2002 Kings Fund and Office of Health Economics London 9 14
13. N. Devlin An introduction to the use of cost-effectiveness thresholds in decision- making: What are the issues? A. Towse C. Pritchard N. Devlin Cost effectiveness thresholds: Economics and ethical issues 2002 Kings Fund and Office of Health Economics London 16 24
14. N. Devlin, D. Parkin, and M. Gold WHO evaluates NICE: The report card is good but incomplete British Medical Journal 327 2003 1061 1062
15. C. Donaldson, and K. Gerard Economics of health care financing. The visible hand 2nd ed. 2005 Palgrave Macmillan Basingstoke
16. P. Doubilet, M.C. Weinstein, and B.J. McNeil Use and misuse of the term "cost effective" in medicine New England Journal of Medicine 314 1986 253 256
17. M. Drummond, G. Torrance, and J. Mason Cost-effectiveness league tables: More harm than good? Social Science & Medicine 37 1993 33 40
18. H. Eichler, S. Kong, W. Gerth, P. Mavros, and B. Jonsson Use of cost-effectiveness analysis in health care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value in Health 7 2004 518 528
19. P. Farquhar, and A. Pratkanis Decision structuring with phantom alternatives Management Science 39 1993 1214 1226
20. A. Gafni, and S. Birch Guidelines for the adoption of new technologies: A prescription for uncontrolled growth in expenditures and to avoid the problem Canadian Medical Association Journal 148 1993 913 917
21. A. Gafni, and S. Birch Preferences for outcomes in economic evaluation: An economic approach to addressing economic problems Social Science & Medicine 40 1995 767 776
22. A. Gafni, and S. Birch QALYs and HYEs: Spotting the differences Journal of Health Economics 16 1997 601 608
23. A. Gafni, and S. Birch NICE methodological guidelines and decision making in the National Health Service in England and Wales Pharmacoeconomics 21 2003 149 157
24. A. Gafni, and S. Birch Inclusions of drugs in provincial drug benefit programs: Should 'reasonable decisions' lead to uncontrolled growth in expenditures? Canadian Medical Association Journal 168 2003 849 851
25. M.R. Gold, J.E. Siegel, L.B. Russel, and M.C. Weinstein Cost-effectiveness in health and medicine 1996 Oxford University Press New York
26. J.S. Hoch, A.H. Briggs, and A.R. Willan Something old, something new, something borrowed, something blue: A framework for the marriage of health econometrics and cost effectiveness analysis Health Economics 11 2002 415 430
27. House of Commons' Select Committee Health: National Institute for Clinical Excellence 2001 Her Majesty's Stationary Office London
28. House of Commons' Select Committee Health: National Institute for Clinical Excellence 2002 Her Majesty's Stationery Office London
29. M. Johannesson The relationship between cost effectiveness analysis and cost benefit analysis Social Science & Medicine 41 1995 483 489
30. A. Laupacis Inclusion of drugs in provincial drug benefit programs: Who is making these decisions, and are they the right ones? Canadian Medical Association Journal 166 2002 44 47
31. A. Laupacis, D. Feeny, A. Detsky, and P.X. Tugwell How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations Canadian Medical Association Journal 146 1992 473 481
32. S. Mayor News extra: NICE estimates that its recommendations have cost the NHS £575 m British Medical Journal 325 2002 924
33. C. Mitton, and C. Donaldson Priority setting toolkit: A guide to the use of economics in healthcare decision-making 2004 BMJ Books London
34. H.M. Nathoe, D. van Dijk, E.W.L. Jansen, W.J.L. Suyker, J.C. Diephuis, and W.J. van Boven A comparison of on-pump and off-pump coronary bypass surgery in low-risk patients New England Journal of Medicine 348 2003 394 402
35. National Institute for Clinical Excellence Technical guidance for manufacturers and sponsors on making a submission to a technology appraisal 2001 National Institute for Clinical Excellence London
36. National Institute for Clinical Excellence Riluzole for Motor Neurone disease - full guidance 2001 National Institute for Clinical Excellence London
37. National Institute for Clinical Excellence (2004). Guide to the Methods of Technology Appraisal. Available from URL: http://www.nice.org.uk/pdf/ brdnov03item3b/pdf (accessed 13 January 2004).
38. B.J. O'Brien, K. Gertsen, A.R. Willan, and L.A. Faulkner Is there a kink in consumers' threshold value for cost effectiveness in health care? Health Economics 11 2002 175 180
39. R. Oostenbrink, J.B. Oostenbrink, K.G.M. Moons, G. Derksen-Lubsen, M.L. Essink-Bot, and D.E. Grobbee Cost utility analysis of patient care in children with meningeal signs International Journal of Technology Assessment in Health Care 18 2002 485 496
40. J.L. Pater, G.P. Browman, M.C. Brouwers, M.F. Nefsky, W.K. Evans, and D.H. Cowan Funding new cancer drugs in Ontario: Closing the loop in practice guidelines development cycle Journal of Clinical Oncology 19 2001 3392 3396
41. M. Rawlins, and A. Culyer National Institute for Clinical Excellence and its value judgements British Medical Journal 329 2004 224 227
42. P. Sendi, A. Gafni, and S. Birch Opportunity costs and uncertainty in the economic evaluation of health care interventions Health Economics 11 2002 23 31
43. A.A. Stinnett, and J. Mullahy Net health benefit: A new framework for the analysis of uncertainty in cost effectiveness analysis Medical Decision Making 18 1998 S68 S80
44. Taylor, R. (2002). Generating national guidelines - a NICE model? Paper presented at the fifth international conference on strategic issues in health care management policy, finance and performance in health care, St. Andrews, Scotland, UK, April 11-13.
45. P.A. Ubel, R.A. Hirth, M.E. Chernew, and A.M. Fendrick What is the price of life and why doesn't it increase at the rate of inflation? Archive of Internal Medicine 163 2003 1637 1641
46. B.B.A. van Hout, M.J. Al, G.S. Gordon, and F.F. Rutten Costs, effects and C/E-ratios alongside a clinical trial Health Economics 3 1994 309 319
47. M. Weinstein, and R. Zeckhauser Critical ratios and efficient allocation Journal of Public Economics 2 1973 147 157
48. M.C. Weinstein, and W.B. Stason Foundation of cost effectiveness analysis for health and medical practices New England Journal of Medicine 296 1977 716 721
49. A.R. Willan, and B.J. O'Brien Sample size and power issues in estimating incremental cost-effectiveness ratios from clinical trial data Health Economics 8 1999 203 211
50. A. Williams What could be nicer than NICE? 2004 Office of Health Economics London
51. A. Williams, and R. Cookson Equity in Health A. Culyer J. Newhouse Handbook on health economics Vol. 1B 2000 North-Holland Amsterdam 1862 1910
52. W.W.C. Winkelmayer, M.C. Weinstein, M.A. Mittleman, R.J. Glynn, and J.S. Pliskin Health economic evaluations: The special case of end stage renal disease treatment Medical Decision Making 22 2002 417 430
53. C. Zinn Plan to cut drug spending attacked by doctors British Medical Journal 324 2002 937